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abstract
PURPOSE The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50)
Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating
risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between
them. We aimed to identify the molecular features that drive the tests and lead to these differences.
PATIENTS AND METHODS Analyses for RS, ROR, EP, and BCI were conducted by the manufacturers in the
TransATAC sample collection that consisted of the tamoxifen or anastrozole arms of the ATAC trial. Estrogen
receptor–positive/human epidermal growth factor receptor 2 (HER2)–negative cases without chemotherapy treat-
ment were included in which all four tests were available (n5 785). Clinicopathologic features included in some tests
were excluded from the comparisons. Estrogen, proliferation, invasion, and HER2module scores fromRS were used
to characterize the respective molecular features. Spearman correlation and analysis of variance tests were applied.
RESULTS There were moderate to strong correlations among the four molecular scores (r 5 0.63-0.74) except
for RS versus ROR (r5 0.32) and RS versus BCI (r5 0.35). RS had strong negative correlation with its estrogen
module (r520.79) andmoderate positive correlation with its proliferation module (r5 0.36). RS’s proliferation
module explained 72.5% of ROR’s variance, while the estrogen module explained only 0.6%. Most of EP’s and
BCI’s variation was accounted for by the proliferation module (50.0% and 54.3%, respectively) and much less
by the estrogen module (20.2% and 2.7%, respectively).
CONCLUSION In contrast to common understanding, RSs are determined more strongly by estrogen-related
features and only weakly by proliferation markers. However, the EP, BCI, and particularly ROR scores are
determined largely by proliferative features. These relationships help to explain the differences in the prognostic
performance of the tests.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
During the past 15 years, several multiparameter
genomic tests have entered mainstream care for pa-
tients with early breast cancer, with some being en-
dorsed for use by authoritative guidelines groups
(ASCO, National Institute for Health and Care Ex-
cellence).1,2 The predominant use of the tests is in the
management of estrogen receptor (ER)–positive pri-
mary disease. All approved tests show prognostic
ability that is beyond that provided by standard clini-
copathologic factors such that patients in whom the
tests indicate excellent prognosis may safely be ex-
cluded from the administration of chemotherapy. The
Oncotype DX Recurrence Score (RS; Genomic Health,
Redwood City, CA) has 16 genes that characterize
tumor biology along with five reference genes and has
been the most widely used test.
Other tests include the Prediction Analysis of Micro-
array 50 (PAM50) Risk of Recurrence (ROR) score
(Prosigna; NanoString Technologies, Seattle, WA),3
EndoPredict (EP; Myriad Genetics, Cologne, Ger-
many),4 Breast Cancer Index (BCI; Biotheranostics,
San Diego, CA),5 and MammaPrint6 (Agendia, Amster-
dam, the Netherlands) that measure 46, 8, 7, and 70
genes, respectively, to characterize tumor biology in
addition to reference genes. All but the last of these
provide an estimate of residual risk of distant recurrence
on the basis that patients will receive 5 years of adjuvant
endocrine therapy. MammaPrint provides a prognostic
estimate if no adjuvant treatment is to be administered.
Understanding the molecular drivers of each of these
tests and how they differ among the tests is key to
interpreting discrepant estimates of risk that are made in
many cases.7,8
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It is widely believed that the RS is dominated by its pro-
liferation module because five of the prognostic 16 genes in
the test sit in the proliferation module and because it has
the largest coefficient of each of the components of the
integrative algorithm.9 An analysis of publicly available gene
expression data from multiple studies involving approxi-
mately 3,000 patients supported the view of the importance
of proliferation genes in the RS.10 It should be noted,
however, that a threshold is applied to the numeric value
given to the prognostic module such that only those cases
with a score above that threshold are differentiated from
one another on the basis of proliferation.9 We have drawn
upon the TransATAC data set of 785 ER-positive/human
epidermal growth factor receptor 2 (HER2)–negative pri-
mary breast cancers to examine the degree to which
proliferation does in fact drive the RS and other molecular
tests in their commercial form as well as consider other
features of the tests that could explain discordances.
PATIENTS AND METHODS
Data were available from TransATAC, a translational study
of samples collected from patients with hormone recep-
tor–positive early-stage breast cancer treated with 5 years of
tamoxifen or anastrozole in the ATAC randomized clinical
trial.11 Women were excluded from this analysis if they
received chemotherapy or had HER2-positive disease. This
study was approved by the South East London Research
Ethics Committee. All patients provided written informed
consent for their tissue to be used in translational research.
RNA was extracted as described before.12 The four tests
included in the current study were the RS, EP, Prosigna
ROR, and BCI. Of note, the last three tests include clinical
factors in their overall score (EP and ROR for all patients,
BCI for node-positive disease), but for the purposes of this
study, only the molecular component of the respective
score was assessed. Molecular analyses were conducted
by the commercial providers of the respective scores using
RNA extracted by Genomic Health.12 The relationship of
the risk estimates with prognosis in the TransATAC sample
set has been described before.12-15 For a sample to be
included in the current analysis, data on all four prognostic
scores had to be available.
To study associations between continuous variables,
Spearman’s rank correlation was used. An analysis of
variance of components of the RS score was conducted.
Genes that constitute the RS modules are listed in Ap-
pendix Table A1 (online only). All statistical analyses were
performed with R 3.6.1 software (R Foundation for Sta-
tistical Computing, Vienna, Austria).
RESULTS
Molecular and clinical data were available for analysis from
785 samples. Clinical characteristics of this cohort are
listed in Table 1. All patients were postmenopausal at di-
agnosis; 55.8% of the tumors were , 2 cm, and 21.4%,
60.3%, and 18.3%were low, intermediate, and high grade,
respectively. The distribution of the molecular scores and
the modules of the RS are listed in Appendix Table A2
(online only). The median values were 15.3 (interquartile
range [IQR], 10.2-22.7) for RS, 40.2 (IQR, 23.5-56.3) for
ROR, 5.5 (IQR, 4.2-7.0) for EP, and 4.8 (IQR, 3.7-5.9) for
BCI. Using the original cutoffs, RS categorized 481, 222,
and 82 patients into the low-, intermediate-, and high-risk
groups, respectively. On the basis of the cutoffs used in the
TAILORx trial, there were 231, 412, and 142 patients in the
low-, intermediate-, and high-risk categories, respectively.
Relationship of RS, ROR, EP, and BCI Molecular Scores
With Clinicopathologic Characteristics
The correlation of each of the scores with patient age, tumor
size, nodal status, and grade is shown in Figure 1. Each of
CONTEXT
Key Objective
We investigated the reasons for the frequently observed differences in estimates of risk of distant recurrence provided by four
widely used commercial molecular profiling tests—Oncotype DX Recurrence Score (RS), Prosigna Risk of Recurrence
(ROR), EndoPredict (EP), and Breast Cancer Index (BCI)—in the TransATAC cohort.
Knowledge Generated
There were strong correlations among the four scores except for RS versus ROR and RS versus BCI. The differences among
the tests were due to RS, against expectations, being dominated by its information on estrogen signaling, and ROR, also
against expectations, being dominated by information on proliferation, while there was an intermediate position for the EP
and BCI.
Relevance
These results should help clinicians to understand the reasons for different estimates of risk for individual patients and may
allow them to give greater weighting to one result over another, depending on the clinical context.
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the scores showed a statistically significant relationship with
grade. This was weak for the RS (r 5 0.27) but moderate
and similar for ROR, EP, and BCI (r 5 0.45-0.50). RS and
EP showed no correlation . 0.20 with age, tumor size, or
nodal status. However, the ROR correlated weakly and
moderately with age and tumor size (r 5 0.29 and 0.32,
respectively), and the BCI had a correlation of 0.23 with
tumor size. None of the signatures showed substantive
correlations with nodal status.
Relationship Among RS, ROR, EP, and BCI
Molecular Scores
The correlation of the overall risk scores with one another is
shown in Figure 2. RS correlated strongly with EP (r 5
0.63) and moderately with ROR (r 5 0.32) and BCI (r 5
0.35) across the whole population. Nonetheless, almost all
patients with an RS $ 31 had ROR and BCI scores above
their respective median values (40.2 for ROR and 4.8 for
BCI). Each of the other three scores correlated strongly with
one another (ROR v EP, r5 0.68; ROR v BCI, r5 0.74; EP
v BCI, r 5 0.67).
Relationship Between RS and Its Constituent Modules
To explore the molecular features driving the risk scores
that may account for the similarities and differences be-
tween them, the RS modules were used in additional
comparisons. The estrogen module had a strong negative
correlation with RS (r 5 20.79). There was a moderate
correlation between RS and its proliferation module
(r 5 0.36; Fig 3). When the proliferation module had
thresholding applied at 6.5 as in the RS algorithm (ie, any
proliferation module value , 6.5 was adjusted to 6.5 by
the algorithm), 614 (78.2%) of 785 samples were allotted
a value of 6.5. The correlation between RS and the
proliferation module with thresholding was r 5 0.52; in
the set of 171 samples where the threshold was not ap-
plied (proliferation module . 6.5), the correlation was
r 5 0.67.
The invasion module had a weak positive association with
RS (r 5 0.26). There was either no association or a mod-
erate association between RS and each of the three indi-
vidual genes not assigned to any of the modules (r 5 0.14
with CD68; r520.43 with GSTM1; r520.36 with BAG1;
Appendix Fig A1, online only).
The HER2 module had no association with RS (r520.04)
in this HER2-negative cohort. Of the 785 samples, 573
(73.0%) had HER2 module scores , 8.0 and had the
threshold value of 8.0 applied. There was no association
between the HER2module and RS when the threshold was
applied (r5 0.16), and in the set of 212 samples above the
HER2 threshold, the correlation with RS was r 5 0.32.
RS’s comparisons with its components is not between
independent measurements, and therefore, the observed
correlations may be overstated. To perform a fair as-
sessment of the contribution of the various molecular
TABLE 1. Clinical Characteristics of the TransATAC Cohort
Characteristic No. (%)
No. of patients 785
Age, years
Mean (SD) 64.4 (8.2)
Range 46.7-88.8
BMI, kg/m2 (63 missing values)
Mean (SD) 27.2 (4.9)
Range 15.9-49.4
Race
White 779 (99.2)
Non-White 6 (0.8)
Nodal status
NA 27 (3.4)
0 541 (68.9)
1-3 175 (22.3)
$ 4 42 (5.4)
Tumor size, cm
, 1 68 (8.7)
1 to , 2 370 (47.1)
2 to , 5 328 (41.8)
$ 5 19 (2.4)
Grade
Low 168 (21.4)
Intermediate 473 (60.3)
High 144 (18.3)
Treatment
Radiotherapy 548 (69.8)
Mastectomy 315 (40.1)
Molecular score
RS
Mean (SD) 17.4 (10.8)
Range 0-65.3
ROR
Mean (SD) 41.1 (20.6)
Range 2.0-93.5
EP
Mean (SD) 5.8 (2.2)
Range 1.0-13.6
BCI
Mean (SD) 4.8 (1.7)
Range 0.5-9.7
Abbreviations: BCI, Breast Cancer Index; BMI, bodymass index; EP,
EndoPredict; NA, not available; ROR, Risk of Recurrence; RS,
Recurrence Score; SD, standard deviation.
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features to their overall score, we assessed how much of
RS’s variance was explained by its module compo-
nents. The estrogen module explained more than half of
RS’s variance (59.1%), while the proliferation module
accounted for approximately a fifth of RS’s information
(19.4%; Table 2). In this cohort, both the invasion and the
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FIG 1. Relationship of the Recurrence Score (RS), Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) molecular scores with
clinical characteristics. Number of positive nodes . 10 was set to 10 in this figure. Spearman’s r correlation coefficients are presented. Tumor sizes
. 50 mm were set to 50 in this figure. Int, intermediate.
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HER2 modules explained very little of RS’s variance
(1.3% and 2.2%, respectively).
Associations of ROR, EP, and BCI With the RS
Proliferation, Estrogen, HER2, and Invasion Modules
We also analyzed the association of proliferation (unthre-
sholded), estrogen, HER2 (unthresholded), and invasion-
related RS module scores with each of the ROR, EP, and
BCI scores. Most of the ROR score’s variance could be
accounted for by RS’s proliferationmodule score (72.5%) and
none by RS’s estrogen module score (0.6%; Table 2; Fig 4).
Half of EP’s variance was accounted for by the proliferation
module (50.0%) and an additional 20.2% by the estrogen
module. The BCI score’s variation was largely accounted for
by the proliferation module (54.3%) and almost none by the
estrogen module (2.7%). Each of ROR, EP, and BCI had very
little association with RS’s HER2 module (explained variance
range, 0.6%-2.4%), and although the correlation of each of
these with the invasion module was . 0.3, the explained
variance ranged between 0.3% and 0.7%.
DISCUSSION
Themajority of patients with early ER-positive breast cancer
will not experience a recurrence when treated with 5 years
of adjuvant endocrine therapy.16 Finding the means to
identify those patients such that they can safely be ex-
cluded from additional adjuvant chemotherapy and/or
extended adjuvant endocrine therapy has been a high
priority over recent years17 and has led to the development
and widespread clinical use of several commercial multi-
parameter gene expression assays, including the four
molecular assays studied here. It is therefore important that
the oncologist interpreting and applying the scores for
patient management have an understanding of the biologic
features the tests reflect, particularly when trying to un-
derstand the difference among their readouts.
To our knowledge, this is the first four-way comparison of
the assays in their commercial form aimed at evaluat-
ing their similarity and molecular drivers. Previously, we
published the prognostic comparison of the four assays in
 = 0.32
0
25
50
75
0 20 40 60
RS
RO
R
ROR v RS
 = 0.63
5
10
0 20 40 60
RS
EP
EP v RS
= 0.35
2.5
5.0
7.5
10.0
0 20 40 60
RS
BC
I
BCI v RS
 = 0.68
5
10
0 25 50 75
EP
EP v ROR 
 = 0.74
2.5
5.0
7.5
10.0
0 25 50 75
BC
I
BCI v ROR 
 = 0.67
2.5
5.0
7.5
10.0
5 10
ROR ROR EP
BC
I
BCI v EP
FIG 2. Scatter plots and Spearman’s r correlation coefficients of the Recurrence Score (RS), Risk of Recurrence (ROR), EndoPredict (EP), and Breast
Cancer Index (BCI) molecular scores in TransATAC.
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their commercial form.8 A number of articles have com-
pared some of the assays,7,18-20 but these have been of
limited sample size and/or based around research as-
says for which comparability with the clinically used
commercial assays is generally poorly documented. Dis-
cordant risk stratification in these studies, however, support
our observations of varying agreement among the molec-
ular scores.
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TABLE 2. Variance of RS, ROR, BCI, and EP Scores as Accounted for by RS’s Four Modules
RS ROR EP BCI
RS Module
Sum of
Squares
Variance
Explained (%)
Sum of
Squares
Variance
Explained (%)
Sum of
Squares
Variance
Explained (%)
Sum of
squares
Variance
Explained (%)
Proliferation
(unthresholded)
17,628 19.4 241,358 72.5 1,878 50.0 1,186 54.3
Estrogen 53,656 59.1 1,799 0.5 759 20.2 59 2.7
Invasion 1,215 1.3 1,610 0.5 24 0.7 5 0.3
HER2
(unthresholded)
1,948 2.2 4,371 1.3 23 0.6 51 2.4
Residuals 16,349 18.0 83,882 25.2 1,067 28.4 880 40.3
NOTE. Residuals show the amount of variance not accounted for by RS’s four modules.
Abbreviations: BCI, Breast Cancer Index; EP, EndoPredict; HER2, human epidermal growth factor receptor 2; ROR, Risk of Recurrence; RS, Recurrence
Score.
6 © 2020 by American Society of Clinical Oncology
Buus et al
Downloaded from ascopubs.org by 86.188.25.172 on November 18, 2020 from 086.188.025.172
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
The availability of the individual gene and gene module
scores that constitute the Oncotype DX RS provided
a unique opportunity to study the degree to which the RS is
driven by these individual features. Using the RS genes and
gene modules as surrogate measures of the designated
biologic features, we were also able to identify the major
differences in the molecular drivers that lead to overall
differences and similarities among the scores.
Of note, this study focused entirely on the molecular
components of the tests and did not include the clinico-
pathologic features that are integrated into the final prog-
nostic result for the ROR, EP, and BCI. We found that other
than the relationship of each score with grade, they had
little relationship with the other features we considered
(age, tumor size, nodal status). Given that these features
are known to have strong prognostic significance, their
statistical independence from each of the scores underlines
the potential for including them in a composite score for
optimal prognostic estimates as we have previously pub-
lished for the RS-pathology-clinical assessment.21 The
stronger correlation of ROR, EP, and BCI (r 5 0.45-0.50)
than RS (r5 0.27) with grade probably reflects the weaker
association of RS with proliferation.
The much weaker association of RS with its proliferation
module than with its estrogen module is superficially sur-
prising given that the coefficient in the Cox model is three
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FIG 4. Associations of the (A) Risk of Recurrence (ROR), (B) EndoPredict (EP), and (C) Breast Cancer Index (BCI) with the proliferation, estrogen, human
epidermal growth factor receptor 2 (HER2), and invasion modules of the Recurrence Score (RS). Spearman’s r correlation coefficients are presented.
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times greater for the proliferation than for the estrogen
module.9 This is at least partly explained by the score from
the proliferation module being thresholded such that in this
series, only 22% of the patients had the proliferation
module unthresholded and therefore contributed mean-
ingfully to the final score. Thresholding of the proliferation
module presumably reflects the prognostic importance of
the modules as measured in the training set of RS.9 Our
earlier analysis of the effect of thresholding on prognostic
estimates with the RS showed the proliferation module
being more informative when thresholding was applied.22
Practitioners should therefore not be surprised if a high RS
tumor is associated with low proliferation as reflected, for
example, by immunohistochemistry for protein encoded by
the MKI67 gene or low grade as reported here.
One might conclude that this TransATAC population is
of relatively good prognosis. Patients who had received
chemotherapy (on the basis of clinicopathologic factors)
were excluded such that outcome for endocrine therapy
alone could be assessed. However, we found that it is
similar to a SEER cohort of . 40,000 patients in terms of
risk as determined by RS reported by Petkov et al.23 For
patients with node-negative disease, 8.0% of the SEER
population had RS$ 31, which was actually lower than the
10.4% for the TransATAC cohort. Similarly, among patients
with node-positive disease, 7.0% of the SEER population
had RS $ 31 compared with 11.1% in TransATAC (Ap-
pendix Table A3, online only). This is likely due to the lower
chemotherapy use (9%) among UK patients on which the
TransATAC collection is based compared with chemo-
therapy use in the overall ATAC cohort (21%).24 As
a consequence, the cohort presented here includes many
patients who would have received chemotherapy had they
been treated in other countries.
The strong inverse correlation of the RS with the estrogen
module indicates that its eventual score is likely to be
particularly influenced by the benefit patients receive from
their endocrine therapy. It may also explain the finding in
our earlier reports in TransATAC where the RS showed
a marked reduction in its prognostic performance between
5 and 10 years, while the ROR, BCI, and EP all showed
continued substantial separation.8 In TransATAC after
5 years, the estrogen module had no prognostic signifi-
cance,22 consistent with patients who showed the strongest
estrogen signaling at diagnosis who lost much of their
benefit from endocrine therapy at its withdrawal. Along with
the pronounced importance of the estrogen module to the
overall RS, this change at 5 years would be expected to lead
to profoundly reduced prognostic performance of the RS
after 5 years. The degree to which this observation in
TransATAC may be generalizable is not known, but it is
supported by the data related to the switching of the im-
portance of estrogen signaling at 5 years being very similar
to that reported by Bianchini et al.25 A meta-analysis from
Early Breast Cancer Trialist Collaborative Group data of
74,194 women with primary ER-positive breast cancer who
were scheduled to have received 5 years of endocrine
therapy also found that higher progesterone receptor ex-
pression reflected better outcomes only in the first 5 years
after surgery and not beyond 5 years.26
The strongest relationship of the other three tests was with
the proliferation module of RS, with proliferation ac-
counting for most of the variance between 50.0% for EP to
72.5% for ROR. The latter very high value may seem
surprising given that the derivation of the ROR is related to
the degree of correlation of a given tumor to each of the
intrinsic subtypes.27 However, as well as these correla-
tions, the algorithm includes a component that is de-
termined by the expression of 18 proliferation-related
genes in the 50-gene panel.28 Clearly, the weighting of
that component results in scores in which proliferation is
the dominant feature.
Our study has a number of strengths. The assays were
carried out by the developers of the commercial assays who
used their proprietary methods and were blinded to the
patients’ clinical and outcome data. The same batch of
RNA extracts were used for all four assays, which allowed
for direct head-to-head comparisons of the scores and
features. Weaknesses include that the module scores
analyzed in this study are surrogates of the biologic features
we assessed and that their direct role can be considered
only with the RS. Nonetheless, the very strong relationships
with proliferation and the individual genes of the estrogen
module being those that are strongly related to estrogen
signaling support the value of these surrogates. Further-
more,. 99% of the cohort was recorded as White, and this
poses some limitation on the generalizability of the findings
to racially more diverse populations.
In summary, we found that despite common thinking, the
Oncotype DX RS was primarily driven by estrogen-related
rather than proliferation-related features in the majority of
tumors in the TransATAC cohort. This is in contrast with the
ROR, EP, and BCI that were dominated by proliferative
features. The generalizability of these findings is supported
by the similarity between the range of RSs in the analyzed
population and that in the SEER database. These findings
may explain the differences and similarities in the prog-
nostic performance of these tests for early and late re-
currence that we and others have reported.
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FIG A1. Associations of the Recurrence Score (RS) with the three RS genes not assigned to RS module: CD68, GSTM1, and BAG1. Spearman’s r
correlation coefficients are presented.
TABLE A1. RS Modules and Genes That Constitute the Modules
RS Module Genes
Proliferation CCNB1, AURKA (STK15), BIRC5 (Survivin), MKI67, MYBL2
Estrogen ESR1, PGR, BCL2, SCUBE2
Invasion MMP11, CTSV (CTSL2)
HER2 ERBB2 (HER2), GRB7
Abbreviations: HER2, human epidermal growth factor receptor 2; RS,
Recurrence Score.
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TABLE A3. Patients in RS Risk Categories in TransATAC and SEER
RS Risk Group (cutoff points 18 and 31), No. (%)
Patient Cohort Low Intermediate High
TransATAC
All patients (n 5 785)
No. 481 (61.3) 222 (28.3) 82 (10.4)
Median RS (IQR) 11.4 (7.8-14.5) 22.8 (19.8-36.3) 37.7 (34.0-45.4)
Node negative (n 5 541)
No. 342 (63.2) 143 (26.4) 56 (10.4)
Median RS (IQR) 11.4 (7.6-14.4) 22.7 (19.8-27.0) 37.6 (33.8-45.7)
Node positive (n 5 217)
No. 124 (57.1) 69 (31.8) 24 (11.1)
Median RS (IQR) 11.4 (7.8-14.9) 22.9 (19.8-25.1) 38.0 (35.0-45.0)
SEER
Node negative (n 5 40,134) 21,760 (54.2) 15,152 (37.8) 3,222 (8.0)
Node positive (n 5 4,691) 2,694 (57.4) 1,669 (35.6) 328 (7.0)
NOTE. As reported by Petkov et al.23
Abbreviations: IQR, interquartile range; RS, Recurrence Score.
TABLE A2. Quartile and IQR Values for the Molecular Scores and RS
Modules in TransATAC
Score Median Q1 Q3 IQR
Molecular scores (theoretical range)
RS (0-100) 15.4 10.2 22.7 12.5
ROR (0-100) 40.2 23.5 56.3 32.8
EP (0-15) 5.5 4.2 7.0 2.9
BCI (0-10) 4.8 3.7 5.9 2.2
RS modules
Proliferation 5.8 5.2 6.4 1.2
Estrogen 9.1 8.5 9.8 1.3
Invasion 7.2 6.6 7.7 1.1
HER2 7.6 7.2 8.0 0.9
Proliferation thresholded 6.5 6.5 6.5 0.0
HER2 thresholded 8.0 8.0 8.0 0.0
Abbreviations: BCI, Breast Cancer Index; EP, EndoPredict; HER2,
human epidermal growth factor receptor 2; IQR, interquartile range; Q,
quartile; ROR, Risk of Recurrence; RS, Recurrence Score.
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